반응식
Br[CH2:2][C:3]([C:5]1[C:6]([C:11]2[CH:16]=[CH:15][CH:14]=[CH:13][CH:12]=2)=[N:7][O:8][C:9]=1[CH3:10])=O.[NH2:17][C:18]1[C:23]([O:24][CH2:25][C:26]2[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=2)=[CH:22][CH:21]=[CH:20][N:19]=1>>[CH2:25]([O:24][C:23]1[C:18]2[N:19]([CH:2]=[C:3]([C:5]3[C:6]([C:11]4[CH:16]=[CH:15][CH:14]=[CH:13][CH:12]=4)=[N:7][O:8][C:9]=3[CH3:10])[N:17]=2)[CH:20]=[CH:21][CH:22]=1)[C:26]1[CH:27]=[CH:28][CH:29]=[CH:30][CH:31]=1참가 물질
3
실험 절차
As described for Example 2, 4-(bromoacetyl)-5-methyl-3-phenylisoxazole (commercially available) (140 mg, 0.5 mmol) was converted, using 2-amino-3-benzyloxypyridine instead of 2-amino-3-methylpyridine, to the title compound (96 mg, 50%) which was obtained as a light yellow solid. MS: m/e=382.3 [M+H]+.
출처 및 근거
- ORD 기록
- ord-62f7fa825a104343a1edb21b492e7b90
- 출처 데이터셋
- uspto-grants-2009_09
- 특허 번호
- US07585874B2
연결된 노트
불러오는 중…